SpectraCure announced preliminary results from clinical study for patient 9 and 10 for treatment of patients with recurrent prostate cancer. The treatment method, called photodynamic therapy means that the patient is given a light-activated drug that accumulates in the tumour. When the cancerous tissue is illuminated using SpectraCure's IDOSE technique, the drug is activated, and the tumour eliminated. The treatment effect is evaluated in the study with magnetic resonance imaging (MR) one week after the treatment. The evaluation of the MR images for the most recently treated patients shows good effect, which is consistent with previous results at the corresponding dose level. The preliminary results also show that the effect in the treated area corresponds well with the treatment plan of SpectraCure's IDOSE system.